XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc., identified in SEC filings under CIK 0001697805, is a clinical-stage biopharmaceutical company operating in the oncology sector. The company filed a 10-Q with the SEC on November 13, 2018, reflecting its status as a reporting public company at that time. Xynomic focused on in-licensing and developing cancer therapeutics, with a particular emphasis on bringing oncology compounds to patients in China and other markets. The Holdings structure is consistent with a post-merger entity, a common configuration following SPAC business combinations in the healthcare and life sciences space. Visit SpacDesk and sign up for full data, filings history, and deal analytics on Xynomic and hundreds of other SPAC-related companies.